The United States esoteric testing market size reached USD 4.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.8% during 2025-2033. The rising prevalence of complex diseases, advancements in personalized medicine, the increasing demand for specialized diagnostic tests, significant technological innovations in genomics and proteomics enhance test accuracy and speed, and growing awareness and the need for preventive healthcare are propelling the growth of the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 4.9 Billion |
Market Forecast in 2033 | USD 8.9 Billion |
Market Growth Rate (2025-2033) | 6.8% |
Increasing Prevalence of Complex and Rare Diseases
The rise in cases of rare and complex conditions necessitates specialized diagnostic tests that go beyond routine laboratory procedures, fueling the demand for esoteric testing. According to industry reports, rare diseases affect over 300 million people worldwide and are gaining recognition as a global health priority. According to the National Organization for Rare Disorders (NORD), a rare disorder is a condition that affects fewer than 200,000 Americans. There are over 10,000 rare diseases that together affect more than 30 million Americans. NORD is dedicated to the identification, treatment, and cure of these diseases through comprehensive education, advocacy, research, and service programs. According to the FDA, in 2023, over half of all the novel drugs and biologics approved by the FDA’s Center for Drug Evaluation and Research (CDER) and the FDA’s Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease or condition.
Significant Technological Advancements
Innovations in molecular diagnostics, genomics, and proteomics enhance the accuracy and speed of tests, making them more effective for early disease detection and personalized treatment. For instance, in November 2023, Roche announced the launch of the LightCycler® PRO System based on the proven gold standard technology of the LightCycler® Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in vitro diagnostics. The LightCycler PRO System further complements Roche's molecular PCR testing portfolio, which includes solutions for a variety of healthcare professionals - from those performing research to those testing patients for cancer, infectious diseases, and other public health challenges. Similarly, in January 2024, Biognosys, a leader in next-generation proteomics services, software, and kits for life sciences research and drug development, announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market-leading performance and sensible, superior economics. P2-based plasma proteomics can be used for human or animal-model proteomics studies and clinical research.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on technology, test type, and end user.
Technology Insights:
The report has provided a detailed breakup and analysis of the market based on the technology. This includes enzyme-linked immunosorbent assay, chemiluminescence immunoassay, mass spectrometry, flow cytometry, polymerase chain reaction, and others.
Test Type Insights:
A detailed breakup and analysis of the market based on the test type have also been provided in the report. This includes infectious disease testing, endocrinology testing, oncology testing, toxicology testing, and others.
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals-based labs and independent and referral labs.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West.
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Technologies Covered | Enzyme-linked Immunosorbent Assay, Chemiluminescence Immunoassay, Mass Spectrometry, Flow Cytometry, Polymerase Chain Reaction, Others |
Test Types Covered | Infectious Disease Testing, Endocrinology Testing, Oncology Testing, Toxicology Testing, Others |
End Users Covered | Hospitals-based Labs, Independent and Referral Labs |
Regions Covered | Northeast, Midwest, South, West |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |